2016 World Health Organization Classification of Central Nervous System Tumors

CONTINUUM Lifelong Learning in Neurology

Volumn 23, Issue 6, Neuro-oncology, 2017, Pages 1531-1547

  Wen, Patrick Y ^a   Huse, Jason T ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ISOCITRATE DEHYDROGENASE;

ASTROCYTOMA; CANCER PROGNOSIS; CENTRAL NERVOUS SYSTEM TUMOR; DIAGNOSTIC ACCURACY; EPENDYMOMA; GANGLIONEUROMA; GLIOBLASTOMA; GLIOMA; GLIOSARCOMA; HEMANGIOPERICYTOMA; HISTOLOGY; HISTOPATHOLOGY; HUMAN; LYMPHATIC SYSTEM TUMOR; MEDICAL TERMINOLOGY; MEDULLOBLASTOMA; MENINGIOMA; NERVE SHEATH TUMOR; NEUROECTODERM TUMOR; OLIGODENDROGLIOMA; PLEOMORPHIC XANTHOASTROCYTOMA; REVIEW; SOLITARY FIBROUS TUMOR; TUMOR CLASSIFICATION; TUMOR DIAGNOSIS; WORLD HEALTH ORGANIZATION; CLASSIFICATION; GENOTYPE; PHENOTYPE;

CENTRAL NERVOUS SYSTEM NEOPLASMS; GENOTYPE; GLIOMA; HUMANS; PHENOTYPE; WORLD HEALTH ORGANIZATION;

EID: 85037157351     PISSN: 10802371     EISSN: 15386899     Source Type: Journal    
DOI: 10.1212/CON.0000000000000536     Document Type: Review

References (48)

1. Ostrom QT Gittleman H Fulop J. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008-2012. Neuro Oncol 2015; 17 (suppl 4): iv1-iv62. doi:10.1093/neuonc/nov189.
2. Zulch KJ, ed. Histological typing of tumours of the central nervous system. Geneva, Switzerland: World Health Organization, 1979.
3. Kleihues P Burger PC Scheithauer BW. The new WHO classification of brain tumours. Brain Pathol 1993; 3 (3): 255-268. doi:10.1111/j.1750-3639.1993.tb00752.x.
4. International Agency for Research on Cancer; Kleihues P Cavenee WK, eds. World Health Organization classification of tumours: pathology and genetics of tumours of the nervous system. Lyon, France: IARC Press, 2000.
5. Louis DN Ohgaki H Wiestler OD. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007; 114 (2): 97-109. doi:10.1007/s00401-007-0243-4.
6. Louis DN Perry A Reifenberger G. The 2016 World Health Organization classification of tumors of the central nervous system: A summary. Acta Neuropathol 2016; 131 (6): 803-820. doi:10.1007/s00401-016-1545-1.
7. International Agency for Research on Cancer; Louis DN Ohgaki H Wiestler OD Cavenee WK, editors. WHO classification of tumours of the central nervous system. 4th ed. Lyon, France: World Health Organization, 2016.
8. Brennan CW Verhaak RG McKenna A. The somatic genomic landscape of glioblastoma. Cell 2013; 155 (2): 462-477. doi:10.1016/j.cell.2013.09.034.
9. Ceccarelli M Barthel FP Malta TM. Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell 2016; 164 (3): 550-563. doi:10.1016/j.cell.2015.12.028.
10. Brat DJ Verhaak RG. Cancer Genome Atlas Research Network. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med 2015; 372 (26): 2481-2498. doi:10.1056/NEJMoa1402121.
11. Eckel-Passow JE Lachance DH Molinaro AM. Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med 2015; 372 (26): 2499-2508. doi:10.1056/NEJMoa1407279.
12. Suzuki H Aoki K Chiba K. Mutational landscape and clonal architecture in grade II and III gliomas. Nat Genet 2015; 47 (5): 458-468. doi:10.1038/ng.3273.
13. Pajtler KW Mack SC Ramaswamy V. The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants. Acta Neuropathol 2017; 133 (1): 5-12. doi:10.1007/s00401-016-1643-0.
14. Sturm D Orr BA Toprak UH. New brain tumor entities emerge from molecular classification of CNS-PNETs. Cell 2016; 164 (5): 1060-1072. doi:10.1016/j.cell.2016.01.015.
15. Ramaswamy V Remke M Bouffet E. Risk stratification of childhood medulloblastoma in the molecular era: The current consensus. Acta Neuropathol 2016; 131 (6): 821-831. doi:10.1007/s00401-016-1569-6.
16. Pajtler KW Witt H Sill M. Molecular classification of ependymal tumors across all CNS compartments, histopathological grades, and age groups. Cancer Cell 2015; 27 (5): 728-743. doi:10.1016/j.ccell.2015.04.002.
17. Northcott PA Korshunov A Witt H. Medulloblastoma comprises four distinct molecular variants. J Clin Oncol 2011; 29 (11): 1408-1414. doi:10.1200/JCO.2009.27.4324.
18. Yan H Parsons DW Jin G. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009; 360 (8): 765-773. doi:10.1056/NEJMoa0808710.
19. Giannini C Scheithauer BW Weaver AL. Oligodendrogliomas: reproducibility and prognostic value of histologic diagnosis and grading. J Neuropathol Exp Neurol 2001; 60 (3): 248-262. doi:10.1093/jnen/60.3.248.
20. Louis DN Perry A Burger P. International Society of Neuropathology-Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol 2014; 24 (5): 429-435. doi:10.1111/bpa.12171.
21. Capper D Weissert S Balss J. Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol 2010; 20 (1): 245-254. doi:10.1111/j.1750-3639.2009.00352.x.
22. Reuss DE Mamatjan Y Schrimpf D. IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: A grading problem for WHO. Acta Neuropathol 2015; 129 (6): 867-873. doi:10.1007/s00401-015-1438-8.
23. Olar A Wani KM Alfaro-Munoz KD. IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas. Acta Neuropathol 2015; 129 (4): 585-596. doi:10.1007/s00401-015-1398-z.
24. Sahm F Reuss D Koelsche C. Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma. Acta Neuropathol 2014; 128 (4): 551-559. doi:10.1007/s00401-014-1326-7.
25. Wiestler B Capper D Sill M. Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma. Acta Neuropathol 2014; 128 (4): 561-571. doi:10.1007/s00401-014-1315-x.
26. Huse JT Diamond EL Wang L. Mixed glioma with molecular features of composite oligodendroglioma and astrocytoma: A true "oligoastrocytoma"? Acta Neuropathol 2015; 129 (1): 151-153. doi:10.1007/s00401-014-1359-y.
27. Qu M Olofsson T Sigurdardottir S. Genetically distinct astrocytic and oligodendroglial components in oligoastrocytomas. Acta Neuropathol 2007; 113 (2): 129-136. doi:10.1007/s00401-006-0142-0.
28. Wilcox P Li CC Lee M. Oligoastrocytomas: Throwing the baby out with the bathwater? Acta Neuropathol 2015; 129 (1): 147-149. doi:10.1007/s00401-014-1353-4.
29. Ohgaki H Kleihues P. The definition of primary and secondary glioblastoma. Clin Cancer Res 2013; 19 (4): 764-772. doi:10.1158/1078-0432.CCR-12-3002.
30. Kleinschmidt-DeMasters BK Aisner DL Birks DK. Epithelioid GBMs show a high percentage of BRAF V600E mutation. Am J Surg Pathol 2013; 37 (5): 685-698. doi:10.1097/PAS.0b013e31827f9c5e.
31. Kleinschmidt-DeMasters BK Aisner DL Foreman NK. BRAF VE1 immunoreactivity patterns in epithelioid glioblastomas positive for BRAF V600E mutation. Am J Surg Pathol 2015; 39 (4): 528-540. doi:10.1097/PAS.0000000000000363.
32. Tanaka S Nakada M Nobusawa S. Epithelioid glioblastoma arising from pleomorphic xanthoastrocytoma with the BRAF V600E mutation. Brain Tumor Pathol 2014; 31 (3): 172-176. doi:10.1007/s10014-014-0192-2.
33. Perry A Miller CR Gujrati M. Malignant gliomas with primitive neuroectodermal tumor-like components: A clinicopathologic and genetic study of 53 cases. Brain Pathol 2009; 19 (1): 81-90. doi:10.1111/j.1750-3639.2008.00167.x.
34. Korshunov A Ryzhova M Hovestadt V. Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers. Acta Neuropathol 2015; 129 (5): 669-678. doi:10.1007/s00401-015-1405-4.
35. Wu G Broniscer A McEachron TA. Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet 2012; 44 (3): 251-253. doi:10.1038/ng.1102.
36. Khuong-Quang DA Buczkowicz P Rakopoulos P. K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathol 2012; 124 (3): 439-447. doi:10.1007/s00401-012-0998-0.
37. Herrlinger U Jones DTW Glas M. Gliomatosis cerebri: no evidence for a separate brain tumor entity. Acta Neuropathol 2016; 131 (2): 309-319. doi:10.1007/s00401-015-1495-z.
38. Ellison DW Kocak M Figarella-Branger D. Histopathological grading of pediatric ependymoma: reproducibility and clinical relevance in European trial cohorts. J Negat Results Biomed 2011; 10: 7. doi:10.1186/1477-5751-10-7.
39. Ramaswamy V Taylor MD. Treatment implications of posterior fossa ependymoma subgroups. Chin J Cancer 2016; 35 (1): 93. doi:10.1186/s40880-016-0155-6.
40. Parker M Mohankumar KM Punchihewa C. C11orf95-RELA fusions drive oncogenic NF-κB signalling in ependymoma. Nature 2014; 506 (7489): 451-455. doi:10.1038/nature13109.
41. Rodriguez FJ Perry A Rosenblum MK. Disseminated oligodendroglial-like leptomeningeal tumor of childhood: A distinctive clinicopathologic entity. Acta Neuropathol 2012; 124 (5): 627-641. doi:10.1007/s00401-012-1037-x.
42. Huse JT Edgar M Halliday J. Multinodular and vacuolating neuronal tumors of the cerebrum: 10 cases of a distinctive seizure-Associated lesion. Brain Pathol 2013; 23: 515-524. doi:10.1111/bpa.12035.
43. Taylor MD Northcott PA Korshunov A. Molecular subgroups of medulloblastoma: The current consensus. Acta Neuropathol 2012; 123 (4): 465-472. doi:10.1007/s00401-011-0922-z.
44. Dang M Phillips PC. Pediatric brain tumors. Continuum (Minneap Minn) 2017; 23 (6 Neuro-oncology): 1727-1757.
45. Strowd RE Blakeley JO. Common histologically benign tumors of the brain. Continuum (Minneap Minn) 2017; 23 (6 Neuro-oncology): 1680-1708.
46. Chmielecki J Crago AM Rosenberg M. Whole-exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors. Nat Genet 2013; 45 (2): 131-132. doi:10.1038/ng.2522.
47. Ohgaki H Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 2005; 64 (6): 479-489. doi:10.1097/01.jnen.0000166799.76946.08.
48. Louis DN Aldape K Brat DJ. cIMPACT-NOW (the consortium to inform molecular and practical approaches to CNS tumor taxonomy): A new initiative in advancing nervous system tumor classification. Brain Pathol 2016. doi:10.1111/bpa.12457.